Context Therapeutics (CNTX) Profit After Tax (2020 - 2026)

Context Therapeutics has disclosed Profit After Tax across 7 years of filings, most recently posting -$8.7 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$8.7 million, down 89.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$40.2 million (down 45.57% YoY), and the FY2025 annual result was -$36.1 million, down 35.17% from the prior year.
• Profit After Tax came in at -$8.7 million for Q1 2026 at Context Therapeutics, up from -$13.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$2.3 million in Q2 2024 to a low of -$17.5 million in Q3 2024.
• The 5-year median for Profit After Tax is -$5.0 million (2023), against an average of -$6.5 million.
• Across the five-year window, Profit After Tax soared 55.01% in 2024 and plunged 291.55% in 2025, its largest moves.
• Context Therapeutics' Profit After Tax stood at -$3.6 million in 2022, then plunged by 90.34% to -$6.8 million in 2023, then jumped by 50.62% to -$3.3 million in 2024, then tumbled by 289.65% to -$13.0 million in 2025, then soared by 33.36% to -$8.7 million in 2026.
• The last three Profit After Tax figures came in at -$8.7 million (Q1 2026), -$13.0 million (Q4 2025), and -$9.7 million (Q3 2025), per Business Quant data.